- Home
- CAPL vs GHRS Comparison
CAPL vs GHRS Comparison
Compare CAPL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- GHRS
- Stock Information
- Founded
- CAPL 1992
- GHRS 2018
- Country
- CAPL United States
- GHRS Ireland
- Employees
- CAPL N/A
- GHRS N/A
- Industry
- CAPL Oil Refining/Marketing
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- CAPL Energy
- GHRS Health Care
- Exchange
- CAPL Nasdaq
- GHRS Nasdaq
- Market Cap
- CAPL 800.9M
- GHRS 774.1M
- IPO Year
- CAPL 2012
- GHRS 2021
- Fundamental
- Price
- CAPL $20.05
- GHRS $13.04
- Analyst Decision
- CAPL
- GHRS Strong Buy
- Analyst Count
- CAPL 0
- GHRS 8
- Target Price
- CAPL N/A
- GHRS $30.63
- AVG Volume (30 Days)
- CAPL 29.5K
- GHRS 303.4K
- Earning Date
- CAPL 11-05-2025
- GHRS 11-13-2025
- Dividend Yield
- CAPL 10.45%
- GHRS N/A
- EPS Growth
- CAPL 100.77
- GHRS N/A
- EPS
- CAPL 1.13
- GHRS N/A
- Revenue
- CAPL $3,522,840,000.00
- GHRS N/A
- Revenue This Year
- CAPL N/A
- GHRS N/A
- Revenue Next Year
- CAPL N/A
- GHRS N/A
- P/E Ratio
- CAPL $17.84
- GHRS N/A
- Revenue Growth
- CAPL N/A
- GHRS N/A
- 52 Week Low
- CAPL $19.50
- GHRS $6.00
- 52 Week High
- CAPL $25.73
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- CAPL 36.18
- GHRS 45.13
- Support Level
- CAPL $20.20
- GHRS $12.67
- Resistance Level
- CAPL $21.13
- GHRS $14.96
- Average True Range (ATR)
- CAPL 0.43
- GHRS 0.75
- MACD
- CAPL -0.12
- GHRS -0.07
- Stochastic Oscillator
- CAPL 5.41
- GHRS 17.21
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.